Olivier Marcq

Olivier Marcq, PhD, serves as Vice President CMC at Tubulis.

Olivier is an expert in bioconjugation therapeutics with more than 15 years of leadership expertise in the pharmaceutical industry encompassing CMC operation and strategy, GMP manufacturing as well as R&D, early and late phase development of biologics, particularly ADCs and conjugate vaccines. Previously, he was working in several positions at Vaxcyte including Senior Director, where he led programs and well as process development and manufacturing activities for multivalent bioconjugate vaccines. Olivier is also the founder and Principal of Omnium Bioconsulting, that provides bioconjugates process development and CMC strategy counseling. His prior experiences also comprise positions at Astellas Pharma, Pfizer and Wyeth, where he led team and projects for the development and manufacturing of ADCs and other bioconjugate therapeutics.

Olivier obtained his PhD in Chemistry at the Université de Bourgogne, France.